Thermogenesis (THMO) Leads the PRISM Pack, Up 27% For the Day
Thermogenesis Holdings (THMO) surged 27% today, leading all of the stocks being tracked by PRISM indexes.
Thermogenesis develops and commercializes automated cell processing technologies in the gene therapy field and is currently housed in the PRISM Medical Diagnostics Index, which is practically even for the day.
THMO has had a strong trading week, but has a long way to go, as the stock is down almost 94% since PRISM began tracking the stock in January of 2020.
About ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. For more information about ThermoGenesis, please visit: www.thermogenesis.com.